| Long name: |
FITC Conjugated, Apolipoprotein CII/APOC2 Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
Anti-FITC Antibody |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
Apolipoprotein CII/APOC2 |
| Specificity: |
This is a highly specific antibody against Apolipoprotein CII/APOC2 |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
KLH conjugated synthetic peptide derived from human Apolipoprotein CII/APOC2 |
| Gene ID number: |
344 |
| Tested applications: |
IF(IHC-P) |
| Recommended dilutions: |
IF(IHC-P)(1:50-200) |
| Crossreactivity: |
Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
The apolipoprotein C gene family encodes four homologous proteins designated apoC-I to -IV, The human apoC-I gene maps to chromosome 19q13, The human apoC-II gene maps to chromosome 19q13, The human apoC-III gene maps to chromosome 11q23 and encodes a protein that may delay catabolism of triglyceride-rich particles by inhibiting lipoprotein lipase and hepatic lipase (8), The human apoC-IV gene maps to chromosome 19q13, the enzyme that hydrolyzes triglycerides in plasma and transfers the fatty acids to tissues (5â, which specifically modulate the metabolism of triglyceride-rich lipoproteins (2), &euro, &ldquo, 10), 2 and encodes a 127 amino acid protein that is primarily expressed in the liver (9, 2 and encodes a 79 amino acid single chain protein that is a necessary cofactor for the activation of lipoprotein lipase, 2 and is expressed primarily in the liver where it is activated when monocytes differentiate into macrophages (3, 4), 7), Apolipoproteins are protein components of plasma lipoproteins (1) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
494nm/518nm |
| Synonyms: |
APC2, APOC 2, APOC2 protein, Apo CII, ApoC II, ApoCII, Apolipoprotein C II, Apolipoprotein C II precursor, ApolipoproteinCII, MGC75082, apoC-II , APC 2, APOC2 |
| Properties: |
Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
Apolipoprotein CII/APOC2 Conjugated |
| Short name: |
FITC Conjugated, Apolipoprotein CII/APOC2 Antibody |
| Technique: |
Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
FITC |
| Alternative name: |
fluorecein coupled, Apolipoprotein CII/apolipoprotein C-II (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
APO-CII and APOC-II, APOC2 and IDBG-306903 and ENSG00000234906 and 344, APOC2 and IDBG-639315 and ENSBTAG00000020558 and 618039, Apoc2 and IDBG-151996 and ENSMUSG00000002992 and 11813, Extracellular, lipoprotein lipase activator activity, this GO :0001523 and retinoid metabolic process and biological process this GO :0005576 and extracellular region and cellular component this GO :0005615 and extracellular space and cellular component this GO :0005769 and early endosome and cellular component this GO :0006629 and lipid metabolic process and biological process this GO :0006869 and lipid transport and biological process this GO :0007603 and phototransduction, this GO :0008047 : enzyme activator activity, this GO :0008047 : enzyme activator activity and also this GO :0008289 : lipid binding and also this GO :0016004 : phospholipase activator activity and also this GO :0042803 : protein homodimerization activity and also this GO :0043274 : phospholipase binding and also this GO :0055102 : lipase inhibitor activity and also this GO :0060230 : lipoprotein lipase activator activity, this GO :0008289 : lipid binding, this GO :0016004 : phospholipase activator activity, this GO :0042803 : protein homodimerization activity, this GO :0043274 : phospholipase binding, this GO :0055102 : lipase inhibitor activity, this GO :0060230 : lipoprotein lipase activator activity, visible light and biological process this GO :0008047 and enzyme activator activity and molecular function this GO :0008289 and lipid binding and molecular function this GO :0010518 and positive regulation of phospholipase activity and biological process this GO :0010898 and positive regulation of triglyceride catabolic process and biological process this GO :0010902 and positive regulation of very-low-density lipoprotein particle remodeling and biological process this GO :0010916 and negative regulation of very-low-density lipoprotein particle clearance and biological process this GO :0016004 and phospholipase activator activity and molecular function this GO :0016042 and lipid catabolic process and biological process this GO :0032375 and negative regulation of cholesterol transport and biological process this GO :0033344 and cholesterol efflux and biological process this GO :0033700 and phospholipid efflux and biological process this GO :0034361 and very-low-density lipoprotein particle and cellular component this GO :0034362 and low-density lipoprotein particle and cellular component this GO :0034363 and intermediate-density lipoprotein particle and cellular component this GO :0034366 and spherical high-density lipoprotein particle and cellular component this GO :0034370 and triglyceride-rich lipoprotein particle remodeling and biological process this GO :0034371 and chylomicron remodeling and biological process this GO :0034372 and very-low-density lipoprotein particle remodeling and biological process this GO :0034382 and chylomicron remnant clearance and biological process this GO :0034384 and high-density lipoprotein particle clearance and biological process this GO :0042157 and lipoprotein metabolic process and biological process this GO :0042627 and chylomicron and cellular component this GO :0042632 and cholesterol homeostasis and biological process this GO :0042803 and protein homodimerization activity and molecular function this GO :0043085 and positive regulation of catalytic activity and biological process this GO :0043086 and negative regulation of catalytic activity and biological process this GO :0043274 and phospholipase binding and molecular function this GO :0043691 and reverse cholesterol transport and biological process this GO :0044281 and small molecule metabolic process and biological process this GO :0045723 and positive regulation of fatty acid biosynthetic process and biological process this GO :0045833 and negative regulation of lipid metabolic process and biological process this GO :0048261 and negative regulation of receptor-mediated endocytosis and biological process this GO :0051006 and positive regulation of lipoprotein lipase activity and biological process this GO :0055102 and lipase inhibitor activity and molecular function this GO :0060230 and lipoprotein lipase activator activity and molecular function this GO :0060697 and positive regulation of phospholipid catabolic process and biological process this GO :0070062 and extracellular vesicular exosome and cellular component this GO :0070328 and triglyceride homeostasis and biological process, apolipoprotein C-II |